Allele-Specific KCNQ1 Antisense Molecules for LQT1 Arrhythmia Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Congenital Long QT Syndrome (LQTS), particularly LQT1, are inadequate as β-blockers are not effective for all patients, and invasive measures like ICDs are necessary for those who do not respond, highlighting the need for more direct therapeutic approaches targeting the mutant KCNQ1 protein.
Innovation Solution
Development of allele-specific antisense molecules, such as siRNAs and shRNAs, that target common SNPs in the KCNQ1 gene, specifically inhibiting the mutant allele to shift the allelic balance and reduce arrhythmic events without affecting the wild-type allele.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If β-blockers are used to treat LQT1, then some patients experience therapeutic benefit, but many patients develop intolerance, refractoriness, or noncompliance
Solution Approach 1:
The invention extracts and targets the specific mutant KCNQ1 allele responsible for LQT1 using allele-specific antisense molecules. By isolating and silencing only the mutant allele while preserving the wild-type allele, the treatment directly addresses the genetic defect without requiring patient compliance with ongoing medication regimens.
Solution Approach 2:
The patent introduces allele-specific antisense molecules as intermediaries that mediate between the mutant KCNQ1 allele and the desired therapeutic effect. These molecules specifically bind to and silence the mutant allele, acting as a precise intermediary mechanism that avoids the compliance issues associated with traditional β-blocker therapy.
2Reliability
If invasive measures like ICDs are implemented for β-blocker nonresponders, then life-threatening arrhythmias are prevented, but treatment complexity and invasiveness increase
Solution Approach 1:
The invention extracts the therapeutic function from invasive devices by directly targeting and silencing the mutant KCNQ1 allele at the molecular level. This eliminates the need for ICDs and other invasive measures by addressing the root genetic cause of arrhythmias.
Solution Approach 2:
The patent replaces the mechanical/electrical intervention of ICDs with a molecular biological approach using allele-specific antisense molecules. This substitution transitions from external device-based arrhythmia management to internal molecular-level correction of the genetic defect.
3Reliability
If allele-specific antisense molecules are designed to target mutant KCNQ1 allele, then specific silencing of mutant allele is achieved, but precise targeting requires high sequence complementarity
Solution Approach 1:
The invention applies local quality by introducing mismatches at specific positions within the antisense molecule sequence. These localized mismatches are strategically placed to differentiate between mutant and wild-type alleles, enabling specific targeting of the mutant allele while maintaining sufficient complementarity for effective silencing.
Solution Approach 2:
The patent changes the sequence parameters of the antisense molecules by introducing controlled mismatches at specific positions. This parameter modification allows differentiation between alleles based on their sequence variations, achieving selective silencing of the mutant allele while preserving wild-type function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense molecules effectively downregulate the mutant KCNQ1 allele by 40-60%, reducing arrhythmic events in human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and potentially shortening action potential duration, thereby preventing life-threatening arrhythmias.
Implementation Method 1
an antisense nucleic acid strand which is substantially complementary to a target region of a transcript encoded by the KCNQ1 gene
Implementation Method 2
antisense molecules effectively downregulate the mutant KCNQ1 allele by 40-60%
Data Source
AI summary
The invention relates to isolated antisense molecule capable of inhibiting the expression of the KCNQ1 gene in a mammalian cell, wherein said antisense molecule comprises an anti-sense nucleic acid strand which is substantially complementary to a target region of a transcript encoded by the KCNQ1 gene, wherein said antisense nucleic acid strand is at least complementary to SNP rs1057128, rs8234 or rs17215465 in said target region.